drugset / Trial / NCT00835692
Clarithromycin 500 mg Tablets Under Fasting Conditions
RandomizedCrossoverOpen-labelOther
Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 500 mg Clarithromycin Tablets with that of 500 mg BIAXIN® Tablets following a single oral dose (1 x 500 mg tablet) in healthy adult subjects under fasting conditions.
Timeline
- Start
- 2002-09
- Primary completion
- 2002-09
- Completion
- 2002-09
Outcome
Met primary endpoint
registry analysis (unspecified test); Clarithromycin vs Biaxin®; Test/Ref Ratio of LS Mean x 100 98.4 (90% CI 91.5 to 106) NCT00835692 ↗
registry analysis (unspecified test); Clarithromycin vs Biaxin®; Test/Ref Ratio of LS Means x 100 93.5 (90% CI 89.6 to 97.6) NCT00835692 ↗
registry analysis (unspecified test); Clarithromycin vs Biaxin®; Test/Ref Ratio of LS Means x 100 93.5 (90% CI 89.5 to 97.7) NCT00835692 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | Oral |
Indications
No indication recorded.